NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification
Open Access
- 22 June 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (9) , 1359-1366
Abstract
Despite its name, the current diagnosis of acute kidney injury (AKI) still depends on markers of decreased kidney function and not on markers of injury. This results in a delayed diagnosis: AKI is diagnosed based on serum creatinine criteria only when the severity of injury is enough to decrease glomerular filtration rate. Moreover, by the time AKI is diagnosed, the insult may have already ceased, and even appropriate therapy targeted at the specific insult and its associated pathogenic pathways may no longer be effective. Biomarkers of injury are needed that allow the diagnosis of AKI based on injury criteria. At least three commercially available immunoassays assessing urinary or plasma neutrophil gelatinase-associated lipocalin and urinary tissue inhibitor of metalloproteinases-2 × insulin-like growth factor-binding protein-7 ([TIMP2]*[IGFBP7]) (NephroCheck®) have generated promising data regarding prediction and early diagnosis of AKI, although their relative performance may depend on clinical context. Recently, a urinary peptidomics classifier (PeptAKI) was reported to predict AKI better than current biomarkers. Focusing on [TIMP2]*[IGFBP7], the cellular origin of urinary TIMP2 and IGFBP7 remains unclear, especially under the most common predisposing condition for AKI, i.e. chronic kidney disease. We now discuss novel data on the kidney cell expression of TIMP2 and IGFBP7 and its clinical implications.Keywords
Funding Information
- FEDER (PI22/00 469, PI22/00 050, PI21/00 251)
- ISCIII-RETIC (RD016/0009)
- Sociedad Española de Nefrología
- Sociedad Madrileña de Nefrología
- FRIAT
- Comunidad de Madrid en Biomedicina (P2022/BMD-7223)
- Instituto de Salud Carlos III (RD21/0005/0001)
- European Union (PMP21/00 109)
- COST (CA21165)
This publication has 44 references indexed in Scilit:
- Kinetic eGFR and Novel AKI Biomarkers to Predict Renal RecoveryClinical Journal of the American Society of Nephrology, 2015
- Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKIJournal of the American Society of Nephrology, 2015
- Cell-cycle arrest and acute kidney injury: the light and the dark sidesNephrology Dialysis Transplantation, 2015
- Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkersNephrology Dialysis Transplantation, 2014
- The Rise and Fall of NGAL in Acute Kidney InjuryBlood Purification, 2014
- Acute Kidney Injury and Chronic Kidney Disease as Interconnected SyndromesNew England Journal of Medicine, 2014
- TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injuryKidney International, 2014
- Pilot study identifying myosin heavy chain 7, desmin, insulin‐like growth factor 7, and annexin A 2 as circulating biomarkers of human heart failureProteomics, 2013
- Discovery and validation of cell cycle arrest biomarkers in human acute kidney injuryCritical Care, 2013
- Region- and Type-Specific Induction of Matrix Metalloproteinases in Post–Myocardial Infarction RemodelingCirculation, 2003